Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting

Autor: Rachael Sorg, Xiting Cao, Caroline McKay, Thomas Burke, Ashwini Arunachalam, David P. Carbone, Amy P. Abernethy
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
Oncology
Male
Lung Neoplasms
Databases
Factual
Cancer Treatment
lcsh:Medicine
Aftercare
Lung and Intrathoracic Tumors
chemistry.chemical_compound
0302 clinical medicine
Maintenance therapy
Carcinoma
Non-Small-Cell Lung
Medicine and Health Sciences
Anaplastic lymphoma kinase
Electronic Health Records
lcsh:Science
Routes of Administration
Aged
80 and over
Multidisciplinary
Pharmaceutics
Middle Aged
Pemetrexed
Treatment Outcome
030220 oncology & carcinogenesis
Female
Anatomy
medicine.drug
Research Article
Clinical Oncology
Adult
medicine.medical_specialty
Histology
Bevacizumab
Context (language use)
Antineoplastic Agents
Carcinomas
03 medical and health sciences
Cancer Chemotherapy
Drug Therapy
Diagnostic Medicine
Internal medicine
Intravenous Injections
medicine
Cancer Detection and Diagnosis
Chemotherapy
Humans
Lung cancer
Survival analysis
Aged
Neoplasm Staging
Retrospective Studies
Pharmacology
business.industry
lcsh:R
Cancers and Neoplasms
Biology and Life Sciences
medicine.disease
Survival Analysis
Carboplatin
United States
Non-Small Cell Lung Cancer
030104 developmental biology
chemistry
lcsh:Q
Clinical Medicine
business
Zdroj: PLoS ONE
PLoS ONE, Vol 12, Iss 6, p e0178420 (2017)
ISSN: 1932-6203
Popis: Purpose To establish a baseline for care and overall survival (OS) based upon contemporary first-line treatments prescribed in the era before the introduction of immune checkpoint inhibitors, for people with metastatic non-small cell lung cancer (NSCLC) without common actionable mutations. Methods Using a nationally representative electronic health record data from the Flatiron dataset which included 162 practices from different regions in US, we identified patients (≥18 years old) newly diagnosed with stage IV NSCLC initiating first-line anticancer therapy (November 2012- January 2015, with follow-up through July 2015). Patients with documented epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) translocation were excluded. Anti-cancer drug therapy and overall survival were described overall, and by histology. Results A total of 2,014 patients with stage IV NSCLC without known EGFR or ALK genomic tumor aberrations initiated systemic anticancer therapy, 22% with squamous and 78% with nonsquamous histology. Their mean (SD) age was 67 (10) years, 55% were male, and 87% had a smoking history. In nonsquamous NSCLC, carboplatin plus pemetrexed either without (25.7%) or with bevacizumab (16%) were the most common regimens; 26.6% of nonsquamous patients receiving induction therapy also received continuation maintenance therapy. In squamous NSCLC, carboplatin plus paclitaxel (37.6%) or nab-paclitaxel (21.1%) were the most commonly used regimens. Overall median OS was 9.7 months (95% CI: 9.1, 10.3), 8.5 months (95% CI: 7.4, 10.0) for squamous, and 10.0 months (95% CI: 9.4, 10.8) for nonsquamous NSCLC. Conclusion The results provide context for evaluating the effect of shifting treatment patterns of NSCLC treatments on patient outcomes, and for community oncology benchmarking initiatives.
Databáze: OpenAIRE
Externí odkaz: